XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements {"summary":"","positive":[],"negative":[],"faq":[]}

#XOMA #XOMAO #XOMAP XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements

www.stocktitan.net/news/XOMA/xoma-royalty-r...

XOMA Royalty Announces CFO Transition XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA) announced today its Chief Financial Officer, Thomas Burns, will be stepping down from his position with XOMA Royalty to pursue other professional opportunities. “Tom’s leadership,

#XOMA #XOMAO #XOMAP XOMA Royalty Announces CFO Transition

www.stocktitan.net/news/XOMA/xoma-royalty-a...

XOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing Agreement for Mezagitamab XOMA Royalty (NASDAQ: XOMA) and Takeda amended their 2006 collaboration via a strategic royalty share transaction announced Dec 30, 2025. Takeda regains a majority of XOMA Royalty’s mezagitamab economics while XOMA Royalty will retain a low single-digit royalty on mezagitamab and up to $13.0 million in milestones (previously mid-single-digit royalty and $16.25 million in potential milestones).In exchange, XOMA Royalty will receive payments (low to mid-single-digit royalties and milestones) tied to a basket of nine development-stage assets from Takeda’s externalized portfolio, including programs from Neurocrine, Mirum, Oak Hill Bio, Recursion, and others.

#XOMA #XOMAO #XOMAP XOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing Agreement for Mezagitamab

www.stocktitan.net/news/XOMA/xoma-royalty-a...

XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements Business development : Secures royalty economic interests in two early stage partnered assets through XOMA Royalty’s announced expected acquisition of LAVA Therapeutics. Company acquisitions : •Completed XOMA Royalty’s acquisitions of Turnstone Biologics and HilleVax; • announced acquisitions of

#XOMA #XOMAO #XOMAP XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements

www.stocktitan.net/news/XOMA/xoma-royalty-r...

XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement XOMA Royalty (Nasdaq: XOMA) and LAVA Therapeutics (Nasdaq: LVTX) amended their share purchase agreement on October 17, 2025.Under the Amendment, tendering LAVA shareholders will receive an initial cash amount of $1.04 per share plus a non-transferable CVR that preserves rights to 75% of net proceeds from partnered assets and unpartnered program exits, and a new contingent right of up to $0.23 per CVR depending on final liability determinations. LAVA’s minimum net-cash closing condition was reduced to $24.5 million (from $31.5 million). The Offer deadline extended to Nov 12, 2025 and closing is expected in Q4 2025, subject to tender thresholds and shareholder approvals.

#XOMA #XOMAO #XOMAP XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement

www.stocktitan.net/news/XOMA/xoma-royalty-a...

XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V. XOMA Royalty (NASDAQ: XOMA) and LAVA Therapeutics (Nasdaq: LVTX) extended the expiration of their tender offer to acquire all outstanding LAVA shares until one minute after 11:59 p.m. ET on October 17, 2025. The Offer pays a cash amount (per the Purchase Agreement) plus a non-transferable CVR per share granting holders 75% of net proceeds from LAVA’s two partnered assets and 75% of net proceeds from any out-license or sale of unpartnered programs. Closing is expected in Q4 2025, subject to conditions including at least 80% (or 75%) tendered shares, shareholder approvals, a minimum cash balance at closing, and other customary conditions. LAVA shareholders have signed support agreements; a shareholder meeting is planned before early November 2025.

#XOMA #XOMAO #XOMAP XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.

www.stocktitan.net/news/XOMA/xoma-royalty-e...

XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements XOMA Royalty (NASDAQ:XOMA) reported Q2 2025 financial results and significant business developments. The company received $29.6 million in royalties and milestones in H1 2025, including $11.7 million in Q2. Notable achievements include the acquisition of multiple companies (Turnstone Biologics, LAVA Therapeutics, and HilleVax) and the $20 million purchase of mezagitamab royalty rights from BioInvent.Q2 2025 financial highlights include net income of $9.2 million and total income/revenue of $13.1 million. The company ended Q2 with $78.5 million in cash and cash equivalents. Several pipeline advancements were reported, including Rezolute's completion of Phase 3 enrollment for ersodetug and EMA's acceptance of Day One's tovorafenib MAA. [ "Received $29.6 million in royalties and milestones in H1 2025", "Net income of $9.2 million in Q2 2025, up from $7.4 million in Q2 2024", "Strategic acquisitions of Turnstone Biologics, LAVA Therapeutics, and HilleVax expanding portfolio", "Strong cash position of $78.5 million as of June 30, 2025", "Multiple pipeline advancements including regulatory milestones and Phase 3 trial progress", "Decreased G&A expenses to $7.8 million in Q2 2025 from $11.0 million in Q2 2024" ]

#XOMA #XOMAO #XOMAP XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements

www.stocktitan.net/news/XOMA/xoma-royalty-r...

XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right XOMA Royalty (NASDAQ: XOMA) has entered into a definitive agreement to acquire LAVA Therapeutics (NASDAQ: LVTX) in a structured deal valued at $1.16 to $1.24 per share in cash, plus a contingent value right (CVR). The CVR entitles shareholders to 75% of net proceeds from LAVA's partnered assets and potential out-licensing of unpartnered programs.The transaction, expected to close in Q4 2025, requires at least 80% shareholder tender and includes specific closing conditions. As part of the deal, LAVA will discontinue its Phase 1 clinical trial of LAVA-1266 for acute myeloid leukemia and myelodysplastic syndrome. The acquisition adds milestone and royalty economics from LAVA's gamma delta bispecific antibodies portfolio to XOMA Royalty's assets.

#XOMA #XOMAO #XOMAP XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right

www.stocktitan.net/news/XOMA/xoma-royalty-e...

HilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right XOMA Royalty (NASDAQ: XOMA) has entered into a definitive merger agreement to acquire HilleVax (NASDAQ: HLVX) in a deal that values HilleVax shares at $1.95 in cash per share plus a contingent value right (CVR).The CVR includes potential additional payments from: (1) excess cash above $102.95 million, (2) 90-100% of savings from Boston office lease obligations, and (3) 90% of proceeds from any norovirus vaccine program sales within specific timeframes. The deal has secured support from 22.9% of HilleVax stockholders, including officers and directors.XOMA Royalty will commence a tender offer by August 18, 2025, with the acquisition expected to close in September 2025. The deal requires a majority of HilleVax shares to be tendered and maintaining a minimum cash balance at closing.

#XOMA #XOMAO #XOMAP HilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right

www.stocktitan.net/news/XOMA/hille-vax-ente...

Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right XOMA Royalty (NASDAQ:XOMA) has announced a definitive merger agreement to acquire Turnstone Biologics (NASDAQ-CM:TSBX). Under the terms of the agreement, XOMA will pay $0.34 in cash per share plus one non-transferable contingent value right (CVR) for each Turnstone share.The acquisition will proceed through a tender offer starting by July 11, 2025, requiring a majority of outstanding shares to be tendered and meeting certain conditions including minimum cash balance requirements. Approximately 25.2% of Turnstone stockholders have already agreed to tender their shares. The merger is expected to close in August 2025.

#XOMA #XOMAO #XOMAP Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right

www.stocktitan.net/news/XOMA/turnstone-biol...

XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million XOMA Royalty Corporation (NASDAQ: XOMA) has acquired BioInvent International's future royalty and milestone rights for mezagitamab (TAK-079) in a deal worth up to $30 million. The transaction includes $20 million paid at closing and an additional $10 million contingent upon mezagitamab receiving FDA marketing approval for IgA nephropathy.With this acquisition and its existing entitlements, XOMA will receive up to $16.25 million in milestones from Takeda and mid-single digit royalties on future mezagitamab commercial sales. Takeda is currently conducting a Phase 3 clinical trial for mezagitamab in immune thrombocytopenia (ITP) patients. The drug is a fully human IgG1 monoclonal antibody targeting CD38-expressing cells, with potential to become best-in-class in its category.

#XOMA #XOMAO #XOMAP XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million

www.stocktitan.net/news/XOMA/xoma-royalty-p...

XOMA Royalty Reports First Quarter 2025 Financial Results and Highlights Business Achievements XOMA Royalty (NASDAQ: XOMA) reported strong Q1 2025 financial results with total income of $15.9 million, up from $1.5 million in Q1 2024. The company received $18.0 million in cash receipts, including $13.4 million in royalties and $4.6 million in milestones. Key achievements include the EMA's acceptance of tovorafenib's MAA, Takeda's Phase 3 trial initiation for mezagitamab, and acquisition of interest in Castle Creek's D-Fi through a $5 million investment. The company ended Q1 with $95.0 million in cash and reported net income of $2.4 million, compared to a net loss of $8.6 million in Q1 2024. XOMA continued its shareholder-focused strategy through share repurchases and pipeline advancement while maintaining strict expense control.

#XOMA #XOMAO #XOMAP XOMA Royalty Reports First Quarter 2025 Financial Results and Highlights Business Achievements

www.stocktitan.net/news/XOMA/xoma-royalty-r...

XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements XOMA Royalty reported its Q4 and full year 2024 financial results, highlighting significant portfolio expansion and business achievements. The company doubled its royalty and milestone portfolio to over 120 assets through five transactions in 2024, including two whole company acquisitions.Key financial metrics include:Q4 cash receipts: $4.0 millionFull-year cash receipts: $46.3 millionQ4 total income: $8.7 millionFull-year total income: $28.5 millionYear-end cash position: $106.4 millionNotable developments include FDA approvals for Day One's OJEMDA™ and Zevra's MIPLYFFA™. The company deployed $65 million to acquire new milestone and royalty assets and paid $5.5 million in dividends. However, XOMA recorded a net loss of $4.0 million in Q4 and $13.8 million for the full year 2024, primarily due to $30.9 million in non-cash credit losses on purchased receivables.

#XOMA #XOMAO #XOMAP XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements

www.stocktitan.net/news/XOMA/xoma-royalty-r...